Market and Technology Trends

Next-Generation Sequencing 2026

Apr 2026

Clinical Dx from high-throughput labs and automated decentralized testing will drive NGS to $8.3B by 2031 - can semiconductor-scale manufacturing support this growth?

YINTR26541

SCOPE

Depth analysis

System
Module
Sub-module
Component
Process
Wafer
Material

Technology

Microfluidics
MEMS
Glass, Silicon
Biosensors (CIS, ISFET, Acoustic)

MARKET

2021-2026-2031 Timeframe
Device units
Value
Wafer (device)
Equipment

PLAYERS

Market shares
Ecosystem / Supply chain
Strategy / Financial analysis
Business news

TECHNOLOGY

Technology status
Technology Roadmap

What’s new

Market forecast:
- Updated market forecasts through 2031, including a revised view of NGS market dynamics segmented by technology generation, applications (R&D and clinical diagnostics), and detection type (optical, electrochemical).
Strategic and ecosystem analysis:
- Overview of global NGS deployment strategies.
- Strategic analysis of key NGS players, including Illumina, Thermo Fisher Scientific, MGI Tech, Oxford Nanopore Technologies, and PacBio.
- Assessment of new entrants such as Element Biosciences, Ultima Genomics, and Roche, and their positioning within the NGS market.
- In-depth analysis of the global NGS ecosystem, from end users to instrument and flow-cell manufacturers.
Supply chain analysis:
- Supply chain assessment of NGS sequencers, from optical components to computing solutions.
Technology roadmap:
- Analysis of key flow-cell technology roadmaps, segmented by micro-structuration and biosensor types.

Report’s objectives

This Yole Group report is an updated version of our 2023 report. Provided herein is a complete analysis of NGS microfluidic components / modules, instruments, applications, markets, and technologies.

This updated version provides:

Significant new trends and evolution in the NGS microfluidics industry’s markets, applications, and business models.
Presentation of the “hot spots” where things are moving, along with future high-potential applications.
Analysis of strategic moves since 2021: M&A, fundraising, etc.
Understanding of the competitive environment through an overview of the key players and the evolution of NGS microfluidics vendor market-share, per segment.
Updated market data and forecasts (in value and volume) up to 2031 for NGS microfluidic components and modules, including insights on the materials market (polymer, glass wafers, silicon wafers).
Supply chain description and analysis.
Latest technology trends (materials, manufacturing, biology, detection methods, etc.).

NGS market maturity is shifting toward clinical Dx

The next-generation sequencing (NGS) market reached about $6.1B in 2025 and is expected to grow at a 5.3% CAGR through 2031, driven by a shift from R&D use toward clinical applications, particularly in oncology, MRD, and infectious diseases. NGS is now a standard tool in leading research institutions, enabled by lower costs, greater technology diversity, and improved data quality.

After peaking in 2021 due to COVID-19-related genomic surveillance, the market entered a flat phase from 2023 to 2025. Currently, the market is restructuring to better meet clinical and regulatory requirements. Large players such as Labcorp, Natera, Guardant Health, and Novogene have built extensive clinical sequencing capabilities, while high-throughput platforms from Illumina, MGI Tech, and Ultima Genomics have accelerated centralized NGS models, particularly in the U.S. and Asia.

Instrument demand has stabilised due to saturation, while consumables are expected to grow faster, supported by expanding clinical adoption. Asia, especially Greater China, represents the main future growth opportunity. Despite renewed momentum, uncertainties remain regarding cost competitiveness versus PCR-based methods, data interpretation, long-term data storage requirements, and the overall economics of NGS in clinical diagnostics.

Disruption in NGS: Why better specs are not enough?

The NGS microfluidics market is led by Illumina, Thermo Fisher Scientific, BGI Group, Oxford Nanopore Technologies (ONT), and PacBio. Illumina remains the dominant reference, benefiting not only from robust performance but also from a strong ecosystem combining a large installed base, validated workflows, reagents, software, and customer support. Competitors have struggled to displace Illumina, even when offering superior specifications. New entrants such as Roche could strengthen competition by leveraging reagent-rental models and bundling sequencing with existing diagnostics offerings.

PacBio and ONT have established strong scientific credibility in long-read sequencing, particularly for microbial genomics, structural variants, and select rare-disease applications. However, adoption remains limited to expert centers due to sample-quality constraints and operational complexity, keeping long-read sequencing a niche relative to short-read technologies. Emerging short-read platforms from Element Biosciences and Ultima Genomics, despite promising accuracy or throughput advantages, have yet to demonstrate decisive market differentiation, highlighting the difficulty of achieving sustainable penetration.

Investment activity has weakened following the post-COVID slowdown, only a few sequencer-focused companies securing funding. M&A activity among NGS service providers remains strong, exemplified by Abbott’s $21B acquisition of Exact Sciences. Looking forward, competition is expected to intensify around nanopore sequencing, supported by innovation from both academic and industrial players, as clinical demand, especially in oncology and infectious diseases, continues to grow.

Semiconductor technologies as enablers of scalable NGS

NGS technologies are entering a phase where growth is driven less by sequencing performance and more by scalability, robustness, and clinical usability. Short-read sequencing by synthesis (SBS) is a highly mature technology that remains well suited to fragmented samples such as FFPE and cfDNA. Further gains in base accuracy now provide limited benefit, as errors are largely mitigated through sequencing depth, UMIs, and advanced bioinformatics rather than chemistry improvements alone. Long-read technologies (PacBio and Oxford Nanopore) uniquely enable haplotype phasing and structural variant detection but face adoption barriers due to stringent DNA quality requirements, workflow variability, and operational complexity. Mid-length, high-accuracy approaches aim to bridge this gap by improving phasing while maintaining broader sample compatibility.

Across all platforms, sample preparation has emerged as the primary technical bottleneck, with DNA damage, library collapse, and inefficient target enrichment dominating performance limitations. Enzymatic alternatives to legacy chemistries show meaningful improvements, while full end-to-end automation remains difficult to implement. To support decentralized testing, NGS systems must evolve toward fully integrated, “push-button” workflows usable by non-specialists. Increasingly, the value of sequencing lies in data interpretability and seamless integration into clinical pipelines, a trend expected to accelerate with AI-driven analysis.

Semiconductor technologies are becoming central enablers of this transition. The shift from microstructured glass to silicon-based flow cells supports tighter feature control, higher throughput, and wafer-scale manufacturing, as illustrated by Illumina’s MiSeq i100. Advances in CMOS image sensors and ISFETs - including pixel shrink, advanced nodes, and on-chip signal processing - enable faster, more integrated sequencing modules. In parallel, biological and solid-state nanopores, including graphene-based approaches, open new opportunities for semiconductor fabrication and integration. As NGS volumes scale toward clinical diagnostics, semiconductor-style manufacturing and integration are increasingly critical to cost, reliability, and automation.